Was diagnose with transverse Myelitis; This spontaneous case was reported by a patient and describes the occurrence of MYELITIS TRANSVERSE (Was diagnose with transverse Myelitis) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 057M21A, 032L20A and 026L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 17-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In November 2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 30-Apr-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-May-2022, the patient experienced MYELITIS TRANSVERSE (Was diagnose with transverse Myelitis) (seriousness criteria disability and medically significant). At the time of the report, MYELITIS TRANSVERSE (Was diagnose with transverse Myelitis) had not resolved.            Patient took second booster on 27 Apr 2022, and by 4 May 2022 patient had right foot drop, right sided numbness, and right leg could not stand up, and was diagnose with Transverse Myelitis, and patient was handicap. Patient stated that patient was hardly walk, and her right leg was numb. Also patient was the picture of health work out every day, did not smoke or drink or was fat, and one day could not walk, the leg drag, had trouble urinating , and moving bowel, and everything was form Moderna. Also she reported to the CDC. Adverse event caused patient to seek medical care (office visit, Urgent care, ER, hospitalized). Patient symptoms was worsened.  Company comment: This is a spontaneous case concerning a 57-year-old, female patient with no reported medical history and with vaccine history of receiving first, second and first booster dose of mRNA-1273 vaccine, who experienced the unexpected serious (disability and medically significant) AESI event of myelitis transverse. The event occurred approximately 4 days after the  second booster dose of mRNA-1273 vaccine administration. Allegedly the events were described as, patient experienced right foot drop, right sided numbness, right leg could not stand up, leg drag, can hardly walk and had trouble urinating and moving bowel. Patient sought consult and was diagnose with transverse myelitis. It was reported that the patient was now a handicap. No other information surrounding the event was reported. The outcome of the event was reported as not resolved. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 57-year-old, female patient with no reported medical history and with vaccine history of receiving first, second and first booster dose of mRNA-1273 vaccine, who experienced the unexpected serious (disability and medically significant) AESI event of myelitis transverse. The event occurred approximately 4 days after the  second booster dose of mRNA-1273 vaccine administration. Allegedly the events were described as, patient experienced right foot drop, right sided numbness, right leg could not stand up, leg drag, can hardly walk and had trouble urinating and moving bowel. Patient sought consult and was diagnose with transverse myelitis. It was reported that the patient was now a handicap. No other information surrounding the event was reported. The outcome of the event was reported as not resolved. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.